MRPL3 is identified as a prognostic biomarker and therapeutic target in lung adenocarcinoma via a lactylation-disulfidptosis gene signature model and experimental validation
Open Access
- 19 May 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1772955
Abstract
Background: Lung adenocarcinoma (LUAD), the most prevalent histological subtype of lung cancer, is a leading cause of global cancer mortality. Its pronounced heterogeneity poses a critical challenge, creating an urgent need for reliable biomarkers to accurately predict patient prognosis. Here, we focus on two critical tumor-promoting factors: lactylation and disulfidptosis. Methods: Differential expression analysis, correlation analysis, and univariate survival analysis were performed using gene expression profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts to screen differentially expressed genes (DEGs), lactylation and disulfidptosis related genes (LDRGs), and prognosis-related genes (PGs). A prognostic model was constructed via LASSO regression, with its efficacy evaluated using calibration plots and decision curve analysis (DCA).The regulatory role of mitochondrial ribosomal protein large subunit 3 (MRPL3) in lung adenocarcinoma (LUAD) progression was validated through both in vivo and in vitro experiments. Results: This model demonstrated reliable predictive performance across the testing set, validation set, and external validation cohorts. MRPL3 was found to be overexpressed in LUAD tissues and correlated with poor prognosis, advanced tumor stage, and an immunosuppressive tumor microenvironment. In vitro , MRPL3 knockdown inhibited LUAD cell proliferation and migration, reduced intracellular lactylation levels, and downregulated glycolysis-related proteins. Under glucose deprivation, MRPL3-knockdown cells exhibited a more stable F-actin cytoskeleton, suggesting evasion of disulfidptosis via XCT suppression. In vivo , MRPL3 knockdown significantly suppressed xenograft tumor growth. Conclusion: Collectively, this study establishes a robust prognostic model for LUAD and clarifies MRPL3’s role in regulating glycolytic-lactate metabolism and disulfidptosis to influence tumor progression and immune microenvironment remodeling. These findings provide a novel potential target and theoretical basis for LUAD prognosis assessment and targeted therapy.Keywords
This publication has 41 references indexed in Scilit:
- NDRG1‐Driven Lactate Accumulation Promotes Lung Adenocarcinoma Progression Through the Induction of an Immunosuppressive MicroenvironmentAdvanced Science, 2025
- GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancerCell Reports, 2025
- Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic cancerTranslational Oncology, 2025
- ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasionCell Metabolism, 2024
- Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinomaComputers in Biology and Medicine, 2023
- Disulfidptosis: disulfide stress–induced cell deathTrends in Cell Biology, 2023
- Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeuticsSeminars in Cancer Biology, 2022
- NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulationGenes & Diseases, 2020
- GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stressRedox Biology, 2018
- Metabolic phenotype of bladder cancerCancer Treatment Reviews, 2016